Most Read Articles
01 Mar 2016
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Kavitha G. Shekar, 08 Feb 2016

One in 7 patients diagnosed with colorectal cancer (CRC) are below the recommended average-risk screening age of 50, according to a population-based cohort study, which suggests the need for CRC screening policy changes.

11 Apr 2016
Surveillance practice in colorectal adenomas could still be improved, as noted in a Dutch community-based study.
Roshini Claire Anthony, 22 Apr 2016
A once-daily oral dose of the direct-acting antiviral agents (DAAs) ledipasvir/sofosbuvir (LDV/SOF) is safe and effective in treating adolescent genotype 1 (GT1) hepatitis C (HCV) patients, according to results of a study presented at the annual meeting of the European Association for the Study of the Liver (EASL) International Liver Congress™ (ILC) 2016 in Barcelona, Spain.

New Product Highlight - Enfagrow A+ Gentlease

01 Apr 2015
ENFAGROW A+® Gentlease – Enteral/nutritional milk powder 370 g, 500 g, 1.2 kg
   •   Scientifically formulated to help meet expert recommendations for daily DHA intake
   •   Provides 75 mg DHA per day in 3 servings. DHA is found abundantly in the brain.
   •   Easy-to-digest, partially-hydrolyzed proteins which are broken down through PHP (Partial Hydrolysation Process) to ease digestion
   •   Designed to help reduce digestive discomfort

Reference:
1. Enfagrow A+® Gentlease MIMS New Product Monograph Form


Further information available in Section 13b, New in This Issue and mims.com.

Full prescribing information is available upon request.


Related MIMS Drugs

Editor's Recommendations
Most Read Articles
01 Mar 2016
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Kavitha G. Shekar, 08 Feb 2016

One in 7 patients diagnosed with colorectal cancer (CRC) are below the recommended average-risk screening age of 50, according to a population-based cohort study, which suggests the need for CRC screening policy changes.

11 Apr 2016
Surveillance practice in colorectal adenomas could still be improved, as noted in a Dutch community-based study.
Roshini Claire Anthony, 22 Apr 2016
A once-daily oral dose of the direct-acting antiviral agents (DAAs) ledipasvir/sofosbuvir (LDV/SOF) is safe and effective in treating adolescent genotype 1 (GT1) hepatitis C (HCV) patients, according to results of a study presented at the annual meeting of the European Association for the Study of the Liver (EASL) International Liver Congress™ (ILC) 2016 in Barcelona, Spain.